 CRANFORD, N.J., June 15, 2021 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome ARDS and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board SAB, effective immediately. 